Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections

Despite advances in antimicrobial therapy and even the advent of some effective vaccines, remains a significant cause of infectious disease, primarily due to antibiotic resistance. Although is commonly treatable with readily available therapeutics, these therapies are not always efficacious, particu...

Full description

Saved in:

Bibliographic Details
Published in:	Antibiotics (Basel) Vol. 10; no. 12; p. 1530
Main Authors:	Proctor, Luke L, Ward, Whitney L, Roggy, Conner S, Koontz, Alexandra G, Clark, Katie M, Quinn, Alyssa P, Schroeder, Meredith, Brooks, Amanda E, Small, James M, Towne, Francina D, Brooks, Benjamin D
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 14-12-2021 MDPI
Subjects:	Antibiotic resistance Antibiotics Antiinfectives and antibacterials Antimicrobial agents Bacteria Bacterial infections Biofilms Catheters combination therapies Cystic fibrosis Disease Drug resistance Drug therapy Epitopes Hospitals immunotherapies Immunotherapy Infections Infectious diseases Monoclonal antibodies Multidrug resistance Nosocomial infections Pathogens Patients Pneumonia polyclonal antibodies Pseudomonas aeruginosa Review Therapeutic applications Therapeutic targets Urogenital system Vaccines Ventilators United States > US immunotherapies Pseudomonas aeruginosa antibiotic resistance antibiotics combination therapies polyclonal antibodies
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Despite advances in antimicrobial therapy and even the advent of some effective vaccines, remains a significant cause of infectious disease, primarily due to antibiotic resistance. Although is commonly treatable with readily available therapeutics, these therapies are not always efficacious, particularly for certain classes of patients (e.g., cystic fibrosis (CF)) and for drug-resistant strains. Multi-drug resistant infections are listed on both the CDC's and WHO's list of serious worldwide threats. This increasing emergence of drug resistance and prevalence of highlights the need to identify new therapeutic strategies. Combinations of monoclonal antibodies against different targets and epitopes have demonstrated synergistic efficacy with each other as well as in combination with antimicrobial agents typically used to treat these infections. Such a strategy has reduced the ability of infectious agents to develop resistance. This manuscript details the development of potential therapeutic targets for polyclonal antibody therapies to combat the emergence of multidrug-resistant infections. In particular, potential drug targets for combinational immunotherapy against are identified to combat current and future drug resistance.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	2079-6382 2079-6382
DOI:	10.3390/antibiotics10121530